GoldenGolden
Advanced Search
Biofire Diagnostics

Biofire Diagnostics

A biotechnology company that detects pathogens and mutations to diagnose syndromic infectious disease

Biofire Diagnostics, LLC is a biotechnology company that provides syndromic infectious disease diagnostic services. The Salt Lake City-based company was founded in 1990. In 2013, the company was acquired by France-based biotechnology and health diagnostics company BioMérieux, becoming BioMérieux’s Global Center of Excellence for Molecular Diagnostics.

Biofire produced the BioFire FilmArray System for comprehensive multiplex PCR testing. The FDA-cleared BioFire System panels test for viruses, bacteria, parasites, yeast, and antimicrobial resistance genes. The company has used its extensive patent portfolio to successfully market nearly 200 products to the clinical, research and military markets. For many pathogens, Biofire has both FDA-cleared and CE-IVD marked assays.

COVID-19

In collaboration with the Department of Defense, BioFire Defense has developed a fully-automated, sample-to-result assay for the specific detection of SARS-CoV-2, the causative agent of COVID-19. The test has been authorized by the FDA under Emergency Use Authorization (EUA). This assay is designed to run on both the BioFire FilmArray 2.0 and BioFire FilmArray Torch Systems, delivering results in about 45 minutes. After meeting initial DoD demand, commercial availability under EUA is anticipated in April of 2020.

In parallel, BioFire Diagnostics is developing new SARS-CoV-2-specific assays for addition to the BioFire FilmArray Respiratory 2 (RP2) Panel. This new panel is named the BioFire Respiratory 2.1 (RP2.1) Panel and is being developed for both the BioFire 2.0 and BioFire Torch Systems. In addition to the detection of SARS-CoV-2, the BioFire RP2.1 Panel will detect 21 additional respiratory pathogens to help clinicians quickly rule in and rule out other common causes of respiratory illness in about 45 minutes. Development of the BioFire RP2.1 Panel is occurring on an accelerated timeline, and submission to the FDA for EUA and 510(k) clearance is anticipated in Q3 of 2020.

Timeline

Funding rounds

People

Name
Role
LinkedIn

Bianca Lui-Sargent

Employee

Charles McNall

Employee

Christopher Thurston

Employee

Emily Mearns

Employee

Eric Judd

Employee

Hope Vasic

Employee

Jay Walther

Employee

Joe McCullagh

Employee

Jordan Baczuk

Employee

Joshua James Wilson

Employee

Kirsen Sullivan

Employee

Nilesh P. Ingle, Ph.D.

Employee

Santosh Kolipaka

Employee

Further reading

Title
Author
Link
Type
Date

Theranos patents at center of lawsuit over startup's COVID-19 tests - Business Insider

Aaron Holmes

Web

March 17, 2020

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.